云顶新耀宣布耐赋康®被纳入《中国成人IgA肾病及IgA血管炎肾炎临床实践指南(2025)》,成为指南首选对因治疗药物

格隆汇
Oct 23

●新版指南推荐对有疾病进展风险的IgA肾病患者进行9个月的布地奈德肠溶胶囊对因治疗,以降低致病性IgA(Gd-IgA1)。●耐赋康®获改善全球肾脏病预后组织(KDIGO)指南推荐,也是目前全球唯一同时获得国际与国内指南推荐的IgA肾病对因治疗药物。●2025版中国IgA肾病指南提出"分层分阶段"的综合治疗理念,强调对因治疗、尽早治疗、长期治疗的重要性。●新版指南首次聚焦致病性半乳糖缺陷型IgA1(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10